Trial Profile
Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 10 Apr 2010
Price :
$35
*
At a glance
- Drugs Palosuran (Primary)
- Indications Diabetic nephropathies; Hypertension
- Focus Registrational; Therapeutic Use
- Acronyms PROLONG
- 10 Apr 2010 New trial record